Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intas Pharma

- PMLiVE

Teva launches asthma social media campaign

Hopes awareness drive will improve inhaler use

ABPI London offices

UK pharma calls on next government to be more ambitious

ABPI wants medicines access to reach levels of other developed nations

- PMLiVE

FDA approves Teva’s Huntington’s disease drug at second attempt

Austedo will treat fatal degenerative disorder chorea

- PMLiVE

Walmsley steps up to chief executive role at GSK

The firm's first female CEO, she takes over from Sir Andrew Witty

UK flag

ABPI delivers wish-list to Hammond ahead of spring budget

Pharma industry has three key requests

Teva launches online cancer portal My Day

Follows social listening project on gender differences in cancer discussions

- PMLiVE

FDA sets August review date for Teva’s movement disorder drug

Could be first approved treatment for tardive dyskinesia

- PMLiVE

Stada opens books to let formal bidding commence

Cinven, Advent International and Bain Capital now have opportunity to revise their bids

- PMLiVE

Advent tops Cinven offer for Stada as third suitor looms

Values the OTC and generics specialist at €3.6bn, with offer open until 27 February

National Institute for Health and Care Excellence NICE logo

Amicus gets NICE green light for Fabry drug

Oral therapy alternative Galafold approved for routine NHS use

AstraZeneca AZ

Generic version of AZ’s Iressa launched in China

Qilu Pharma’s Yiruike licensed as first-line NSCLC treatment

ABPI London offices

Norgine UK re-joins ABPI

Firm resigned its membership in 2008 in protest over lack of representation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links